Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. [PDF]
Spadafora L +16 more
europepmc +1 more source
Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]
Aparicio-Minguijón E +8 more
europepmc +1 more source
Bruton tyrosine kinase inhibitors and invasive aspergillosis and mucormycosis: a case report and multi-center exploratory retrospective study. [PDF]
Bhaimia E, Russell D, Santos CAQ.
europepmc +1 more source
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]
Hur JY +10 more
europepmc +1 more source
<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study. [PDF]
Haméon C +9 more
europepmc +1 more source
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]
Shah BD, Xue M, Furnback W, Yang K.
europepmc +1 more source
Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges. [PDF]
Wang Y +5 more
europepmc +1 more source
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib. [PDF]
Broccoli A +3 more
europepmc +1 more source
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. [PDF]
Heyman BM +16 more
europepmc +1 more source

